The FDA has expanded the approval of Evkeeza® (evinacumab-dgnb) to include children aged 1 year and older with homozygous familial hypercholesterolemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback